Biopharmaceuticals

Seattle – September 24, 2026 -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) announced that President and CEO Steven Quay, M.D., Ph.D., will serve as a panelist at the 13th Aging Research and Drug Discovery Meeting (ARDD 2026), scheduled for October 1-3, 2026, at the David Rubenstein Treehouse at Harvard University in Boston.

Quay joins regulatory and academic leaders to discuss clinical pathways for aging-related diseases

The panel, titled "Clinical Trials in Diseases of Aging: From Evidence to New Therapeutics and Regulatory Pathways," is set for Thursday, October 1, 2026, from 11:20 a.m. to 12:00 p.m. ET. The session will be moderated by Sebastien Thuault, Editor at Nature Medicine, and will include Jill Lee, Director of Regulatory Policy & Intelligence at Novo Nordisk; Calum MacRae, Professor at Mass General Brigham; and Steve Horvath, Professor at UCLA.

Philadelphia and Boston – September 24, 2026 -- Minaris, a global cell and gene therapy CDMO, has partnered with synthetic biology firm Asimov to integrate proprietary OXGENE viral vector technology into Asimov's AAV Edge producer cell lines, targeting higher manufacturing titers and improved product quality for adeno-associated virus (AAV) gene therapies.

Stable production systems aim to replace costly transient manufacturing

Most AAV programs currently rely on transient production, requiring multiple GMP plasmids to be transfected for every batch. This method drives up costs, limits scalability, and can produce inconsistent product quality. Stable production systems have historically been difficult to develop due to the complexity and interdependency of viral genetics involved.

London and Boston – September 24, 2026 -- Basecamp Research has closed a $140 million oversubscribed Series C financing to train new EDEN foundation models and push a pipeline of AI-designed therapeutics toward clinical development.

S32 leads a syndicate spanning NVIDIA, Anthropic-adjacent backers and sovereign funds

The round was led by S32, with participation from NVIDIA, Menlo Ventures' Anthology Fund, Catalio Capital Management, European Tech Collective, Firebrand River Capital, Inception Fund, King Philanthropies, NATO Innovation Fund, PostScriptum, Redalpine, The Rockefeller Foundation, Singular, Sovereign AI and True Ventures. Andy Conrad, General Partner at S32 and former CEO of Google's Verily, joins Basecamp's Board of Directors.

Dover, Del. – September 24, 2026 -- Clywedog Therapeutics, Inc. reported that its investigational menin inhibitor balomenib produced a placebo-adjusted mean HbA1c reduction of 0.77% at Week 12 (p0.01) and 0.70% at Week 16 (p0.05) in a Phase 1b trial, effects recorded three months after the drug's final dose following just three weeks of treatment.

North Bethesda, Md. – September 24, 2026 -- The International Society for Pharmaceutical Engineering (ISPE) will convene its 2026 Annual Meeting & Expo in Washington, D.C. from October 18-21, drawing pharmaceutical manufacturing leaders for four days of hybrid sessions combining in-person and virtual attendance.

Lonza and Eli Lilly executives headline keynote lineup on manufacturing innovation

Wolfgang Wienand, PhD, CEO of Lonza, will present "The Lonza Engine: Manufacturing the Medicines of Tomorrow," while Kevin Trivett, Senior Vice President of Device and Packaging Operations Manufacturing at Eli Lilly and Company, delivers "Lilly: Embracing Technology to Reach Patients." Additional featured speakers include Marla Phillips, PhD, CEO and President of Pathway for Patient Health LLC, addressing AI and human oversight in manufacturing loops, and cancer survivor and research advocate Jamie Valvano.

Stockholm – September 24, 2026 -- Sobi (STO: SOBI) will present new clinical data on its rare-disease drug Gamifant (emapalumab) at the 2026 Annual Meeting of the Histiocyte Society (HS2026), running September 26-29 in Rotterdam, the Netherlands, with a pooled survival analysis nominated for the meeting's top poster prize.

Pooled transplant-survival analysis earns Robert J. Arceci Prize nomination

The accepted abstract set includes a new pooled analysis of pre- and post-transplant survival outcomes in primary haemophagocytic lymphohistiocytosis (HLH), drawing on data across three prospective trials. Sobi said the analysis was selected as one of the ten highest-scoring poster abstracts at HS2026 and has been nominated for the Robert J. Arceci Prize for Best Poster.

Barcelona – September 24, 2026 -- Daewoong Pharmaceutical has completed enrollment of 104 idiopathic pulmonary fibrosis (IPF) patients in its global Phase 2 trial of Bersiporocin (DWN12088), with top-line results now expected in the first half of 2027.

Trial spans South Korea and the US with balanced enrollment

Of the 104 patients, 55 (52.9%) were enrolled in South Korea and 49 (47.1%) in the United States. The company presented full baseline patient characteristics at the European Respiratory Society (ERS) Congress 2026 in Barcelona on September 6, following interim data shared earlier at KATRDIC 2025.

Tokyo – September 24, 2026 -- Astellas Pharma Inc. (TSE: 4503) has dosed the first patient in a Phase 3 study evaluating setidegrasib, an investigational KRAS G12D-targeted protein degrader, against docetaxel in previously treated non-small cell lung cancer (NSCLC) patients carrying the KRAS G12D mutation.

Trial targets patients who progressed on chemotherapy and checkpoint inhibitors

The randomized, open-label study will enroll approximately 356 patients across multiple countries whose locally advanced or metastatic NSCLC has progressed after platinum-based chemotherapy and checkpoint inhibitor therapy. Dual primary endpoints are progression-free survival, assessed by blinded independent central review, and overall survival.

Pune, India – September 24, 2026 -- The global bladder cancer treatment market was valued at $5.13 billion in 2025 and is projected to reach $11.33 billion by 2034, expanding at a 9.2% compound annual growth rate, according to a new analysis from Maximize Market Research.

Immunotherapy and antibody-drug conjugates drive treatment shift

Adoption of immune checkpoint inhibitors, antibody-drug conjugates (ADCs), and FGFR inhibitors is accelerating across non-muscle-invasive and muscle-invasive bladder cancer segments. Pharmaceutical companies are directing R&D spend toward intravesical drug delivery, gene therapy, and biomarker-driven precision oncology to improve outcomes for recurrent and metastatic urothelial cancer patients.

London – September 24, 2026 -- Artemis Growth Partners, a global investment firm specializing in regulated medical cannabis and emergent medicinal therapeutics, has appointed James Hayward as Advisory Director following his 35-year career at JPMorgan.

Hayward built JPMorgan's European hedge fund credit franchise over three decades

Hayward founded and led JPMorgan's European hedge fund credit business, working across leveraged finance, high yield, credit derivatives and distressed markets. He will now advise Artemis on capital formation, business development, LP relationships and strategic financing across its global platform, working alongside Co-Founder and CIO William Muecke and Managing Partner E. Stanton McLean.